<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480763</url>
  </required_header>
  <id_info>
    <org_study_id>V114-016</org_study_id>
    <secondary_id>V114-016</secondary_id>
    <secondary_id>2017-004024-30</secondary_id>
    <nct_id>NCT03480763</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed 1) to evaluate the safety, tolerability, and immunogenicity of V114
      and Prevnar 13™ in healthy adults 50 years of age or older, 2) to describe the safety of
      sequential administration of V114 or Prevnar 13™ followed by PNEUMOVAX™23, and 3) to evaluate
      the immune responses to the 15 serotypes contained in V114 when PNEUMOVAX™23 is given
      approximately 12 months after receipt of either V114 or Prevnar 13™.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 25, 2018</start_date>
  <completion_date type="Anticipated">December 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to Day 5 after Vaccination 1 and Vaccination 2</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be redness, swelling, and pain/tenderness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to Day 14 after Vaccination 1 and Vaccination 2</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be muscle pain, joint pain, headache, and tiredness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Vaccine-related Serious Adverse Event</measure>
    <time_frame>Up to Month 13</time_frame>
    <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA)</measure>
    <time_frame>Month 13</time_frame>
    <description>Serotype-specific OPA will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific Immunoglobulin G (IgG)</measure>
    <time_frame>Day 30, Month 12 (before Vaccination 2), and Month 13</time_frame>
    <description>Serotype-specific IgG will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Serotype-specific OPA</measure>
    <time_frame>Day 30 and Month 12 (before Vaccination 2)</time_frame>
    <description>Serotype-specific OPA will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) in Serotype-specific OPA</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Serotype-specific OPA will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific IgG</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Serotype-specific IgG will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific OPA</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Serotype-specific OPA will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific IgG</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Serotype-specific IgG will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific OPA</measure>
    <time_frame>Day 1 (Baseline) and Month 12 (before Vaccination 2)</time_frame>
    <description>Serotype-specific OPA will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific IgG</measure>
    <time_frame>Day 1 (Baseline) and Month 12 (before Vaccination 2)</time_frame>
    <description>Serotype-specific IgG will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific OPA</measure>
    <time_frame>Day 1 (Baseline) and Month 12 (before Vaccination 2)</time_frame>
    <description>Serotype-specific OPA will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific IgG</measure>
    <time_frame>Day 1 (Baseline) and Month 12 (before Vaccination 2)</time_frame>
    <description>Serotype-specific IgG will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific OPA</measure>
    <time_frame>Day 1 (Baseline) and Month 13</time_frame>
    <description>Serotype-specific OPA will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific IgG</measure>
    <time_frame>Day 1 (Baseline) and Month 13</time_frame>
    <description>Serotype-specific IgG will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific OPA</measure>
    <time_frame>Day 1 (Baseline) and Month 13</time_frame>
    <description>Serotype-specific OPA will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific IgG</measure>
    <time_frame>Day 1 (Baseline) and Month 13</time_frame>
    <description>Serotype-specific IgG will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific OPA</measure>
    <time_frame>Month 12 (Baseline) and Month 13</time_frame>
    <description>Serotype-specific OPA will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific IgG</measure>
    <time_frame>Month 12 (Baseline) and Month 13</time_frame>
    <description>Serotype-specific IgG will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific OPA</measure>
    <time_frame>Month 12 (Baseline) and Month 13</time_frame>
    <description>Serotype-specific OPA will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific IgG</measure>
    <time_frame>Month 12 (Baseline) and Month 13</time_frame>
    <description>Serotype-specific IgG will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose</description>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine with serotypes1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 ml dose</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PNEUMOVAX™23</intervention_name>
    <description>23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose</description>
    <arm_group_label>V114</arm_group_label>
    <arm_group_label>Prevnar 13™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female in good health

          -  Female participant: not pregnant, not breastfeeding and 1) not of childbearing
             potential, or 2) of childbearing potential and agrees to practice contraception
             through 6 weeks after administration of study vaccine.

        Exclusion Criteria:

          -  History of invasive pneumococcal disease

          -  Known hypersensitivity to any vaccine component

          -  Known or suspected impairment of immune function

          -  Coagulation disorder contraindicating intramuscular vaccination

          -  History of malignancy ≤5 years before enrollment, except for adequately treated basal
             cell or squamous cell skin cancer or in situ cervical cancer

          -  Female participant: positive urine or serum pregnancy test

          -  Prior administration of any pneumococcal vaccine

          -  Received systemic corticosteroids for ≥14 consecutive days and have not completed
             within 30 days of enrollment

          -  Received immunosuppressive therapy

          -  Received a blood transfusion or blood products within 6 months of enrollment

          -  Participated in another clinical study of an investigational product within 2 months
             of enrollment

          -  Current user of recreational or illicit drugs or history of drug or alcohol abuse or
             dependence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>Aluminum phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

